A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results

by Brown, J., Brown, S.R, Coleman, R., Eastell, R., Gath, J., Howell, S., Kendall, J., MacPherson, I., Murden, G., Palmieri, C., Purohit, K., Rathbone, E., Taylor, C., Twelves, C., Wilson, C., Winter, M.
Published 2022

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant

by Ballestrero, A., Benelli, M., Bergqvist, M., Bernardo, A., Bliss, J.M, Bonetti, A., Breast International Group and PYTHIA Collaborators, Cameron, D., Colleoni, M., Davies, D.M, De Swert, H., Duhoux, F.P, Fumagalli, D., Gebhart, G., Henry, S., Hilbers, F.S, Ignatiadis, M., International Breast Cancer Study Group, Jerusalem, G., Kammler, R., Loi, S., MacPherson, I.R, Maibach, R., Malorni, L., McCartney, A., Migliaccio, I., Neven, P., Papadimitriou, K., Piccart, M., Regan, M.M, Ruepp, B., Seles, E., Thomson, A., Tyekucheva, S., Zoppoli, G.
Published 2022